Barriers to adoption of biosimilar insulins in Europe: A mixed-methods study.

ABSTRACT:

Background

Despite the introduction of biosimilar insulins to improve affordability and enhance patient access, their adoption remains limited in Europe.

Objectives

This study aims to (i) provide an up-to-date overview of EMA-approved insulin products and their reimbursement status across selected European countries, and (ii) explore the key factors influencing physicians' prescribing decisions regarding biosimilar and originator insulin.

Methods

A mixed-method design was applied, comprising (i) a quantitative analysis of EMA-approved insulin products and their reimbursement status in nine European countries, and (ii) semi-structured interviews with physicians (N = 20).

Results

Between 1996 and 2022, 43 insulin products received EMA approval, including six bios

SUBMITTER: Car E 

PROVIDER: S-EPMC12515786 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature